Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 5Completed 5Active not recruiting 3Withdrawn 2Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Carcinoma, Hepatocellular 1

Interventions

Docetaxel 11Prednisone 10Leuprolide 10Magnetic Resonance Spectroscopy 9bicalutamide 8Radiotherapy 7Abiraterone Acetate 7Biopsy 6gallium 68 PSMA-11 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Surveys and Questionnaires 5Metformin 5Goserelin 5radium Ra 223 dichloride 4enzalutamide 4apalutamide 4Specimen Handling 4Injections 4Androgen Antagonists 4pembrolizumab 3orteronel 3cabazitaxel 3abiraterone 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Pioglitazone 3Paclitaxel 3Exercise 3Brachytherapy 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Prostatic Neoplasms × 68Ga-DKFZ-PSMA-11 × Clear all
NCT05034562 2024-03-07

Gallium-68 PSMA-11 PET in Participants With Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT02810886 2017-08-22

ProsPERo

Jules Bordet Institute

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡